-
Home
-
Product
-
IMMUNOHISTOCHEMISTRY
-
INSTRUMENT
-
MOLECULAR
-
HISTOLOGY
-
CYTOLOGY
-
DIGITAL PATHOLOGY
-
-
Solution
-
Support
-
About
-
Contact
PRODUCT CATEGORY
PRODUCT CATEGORY
CONTACT US
Phone
Email
Address
ZhengZhou (HQ), Shenzhen (R&D Center), Suzhou (R&D Center), China
RET Breakapart
Clinic Significance：
1.This occurs in 1-2% of patients with non-small cell lung adenocarcinoma
2.The expression was lower in normal lung tissue, and the gene rearrangement activated the kinase active domain of RET, and the expression was higher in lung cancer samples.
Three targeted drugs, Vandetanib, Sorafenib and Sunitinib, inhibit the activity of multiple receptor tyrosine kinases including RET, and to kill cells carrying RET fusion gene.
Chat
message
Quote
Contrast
RET Normal
RET Breakapart
More Info
Probe Description: RET
Cat.No.: CF1019
Specification: 10 tests/box, 20 tests/box
Related Product
